GE HealthCare Technologies Inc. GEHC has received the FDA’s approval for an updated label for its positron emission ...

The FDA label update boosts GE HealthCare’s Vizamyl to a market advantage despite the emergence of blood-based tests.

GE HealthCare (GEHC) announced that the U.S. Food and Drug Administration has approved an updated label for its positron emission tomography or PET imaging agent Vizamyl (flutemetamol F 18 injection) ...

Dr. Nicholas Milano of Medical University of SC says medications such as Lecanemab and donanemab give Alzheimer's patients ...

The revised label expands the brain-scan agent's use, and means that Vizamyl can now be used to diagnose Alzheimer's and predict the development of dementia due to disease, the company said. The ...

FDA Approves Expanded Indications for GE HealthCare’s Vizamyl PET Imaging Agent for Beta Amyloid Detection, Enabling More Precise Care for Alzheimer’s Patients ...

Insulin resistance detected by routine triglyceride-glucose (TyG) index can flag people with early Alzheimer's who are four ...

A new clinical trial to treat Parkinson’s disease will start in Perth next year using a drug currently being tested as a ...

Highlight brain imaging analysis solutions, including 'Neurophet AQUA AD', which monitors side effects from Alzheimer's ...

Merry Life Biomedical Company announces the launch of its global Phase II clinical trial for TML-6, a novel oral small molecule drug targeting early-stage Alzheimer's disease (AD). TML-6 combines ...

Taking inspiration from the CAR T-cell technology used to provide personalized cancer treatments, researchers have conducted ...